Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | KDM4A | O75164 | 2/20 | 0.58 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.58 |
| ▸ | KDM6B | O15054 | 1/20 | 0.58 |
| ▸ | KDM6A | O15550 | 1/20 | 0.58 |
| ▸ | TET3 | O43151 | 1/20 | 0.58 |
| ▸ | KDM4B | O94953 | 1/20 | 0.58 |
| ▸ | KDM5C | P41229 | 1/20 | 0.58 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.58 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.58 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.58 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.58 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.58 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.58 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.58 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17047336 | 0.86 | KDM4E (0.56) | KMT2ATP53KDM4EL3MBTL1KDM4A | |
| SCHEMBL6962756 | 0.86 | KDM4E (0.68) | KMT2ATP53KDM4EL3MBTL1KDM4A | |
| SCHEMBL31547885 | 0.86 | KDM4E (0.56) | KMT2ATP53KDM4EL3MBTL1KDM4A | |
| SCHEMBL69673 | 0.85 | KDM4E (0.77) | KMT2ATP53KDM4EL3MBTL1KDM4A | |
| SCHEMBL16861478 | 0.85 | KMT2A (0.51) | KMT2ATP53KDM4EL3MBTL1KDM4A | |
| SCHEMBL20515237 | 0.85 | KDM4E (0.59) | KMT2ATP53KDM4EL3MBTL1KDM4A | |
| SCHEMBL23359872 | 0.81 | KMT2A (0.47) | KMT2ATP53KDM4EL3MBTL1KDM4A | |
| SCHEMBL15054071 | 0.81 | KDM4E (0.62) | KMT2ATP53KDM4EL3MBTL1KDM4A | |
| SCHEMBL23360051 | 0.81 | KMT2A (0.53) | KMT2ATP53KDM4EL3MBTL1KDM4A | |
| SCHEMBL31056854 | 0.81 | KDM4E (0.62) | KMT2ATP53KDM4EL3MBTL1KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114654819-A | Corrosion-resistant waterproof wallpaper for laboratory and preparation method thereof | 吕寒青 | 2022-06-24 | — | — | CN | claimed |
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| US-20240409536-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2024-12-12 | — | — | US | disclosed |
| EP-4395891-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-114867719-B | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2024-06-25 | — | — | CN | disclosed |
| CN-118234724-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2024-06-21 | — | — | CN | disclosed |
| US-11970448-B2 | Monomers capable of dimerizing in an aqueous solution, and methods of using same | CORNELL UNIVERSITY (US) | 2024-04-30 | — | — | US | disclosed |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| WO-2023034811-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023034811-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| US-8273882-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2012-09-25 | — | — | US | disclosed |
| CN-102036963-A | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors | NOVARTIS AG | 2011-04-27 | — | — | CN | disclosed |
| EP-2282995-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2009141386-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009141386-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| WO-2007028789-A1 | QUINAZOLINE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028789-A1 | QUINAZOLINE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970448-B2 | Monomers capable of dimerizing in an aqueous solution, and methods of using same | CALCOCO2, MDN1, MBNL1 | KMT2A 4317/4885TP53 472/4885KDM4E 4611/4885 |
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | ABL1, NQO2, MAP4K5 | KMT2A 1289/4885TP53 1291/4885KDM4E 980/4885 |
| US-20240409536-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | KMT2A 3214/4885TP53 985/4885KDM4E 3046/4885 |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | KMT2A 2822/4885TP53 102/4885KDM4E 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.